Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases

Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers (Basel). 2021;13:2927.

Article  CAS  PubMed  Google Scholar 

Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken). 2020;5: e1274.

Article  PubMed  Google Scholar 

Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3:1069–77.

Article  PubMed  PubMed Central  Google Scholar 

Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14:244–8.

Article  CAS  PubMed  Google Scholar 

Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4:34.

Article  PubMed  PubMed Central  Google Scholar 

Elias SG, Adams A, Wisner DJ, Esserman LJ, van T Veer LJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1464–83.

Article  CAS  PubMed  Google Scholar 

Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123–5.

Article  PubMed  Google Scholar 

Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:2736–40.

Article  PubMed  Google Scholar 

Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.

Article  PubMed  Google Scholar 

Yeh R-H, Yu J-C, Chu C-H, Ho C-L, Kao H-W, Liao G-S, et al. Distinct MR imaging features of triple-negative breast cancer with brain metastasis. J Neuroimaging. 2015;25:474–81.

Article  PubMed  Google Scholar 

Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast cancer brain metastasis: the potential role of MRI beyond current clinical applications. Cancer Manag Res. 2020;12:9953–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoefnagel LDC, van de Vijver MJ, van Slooten H-J, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12:R75–R75.

Article  PubMed  PubMed Central  Google Scholar 

Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22:1173–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer. 2016;114:793–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang S, Chesney J, Trent JO, Telang S. Abstract 2519: Targeting glucose metabolism in HER2+breast cancer. Cancer Res. 2021;81:2519–619.

Article  Google Scholar 

Farhadi P, Yarani R, Valipour E, Kiani S, Hoseinkhani Z, Mansouri K. Cell line-directed breast cancer research based on glucose metabolism status. Biomed Pharmacother. 2022;146: 112526.

Article  CAS  PubMed  Google Scholar 

Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumour 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.

Article  PubMed  Google Scholar 

Nitchingham A, Pereira JV, Wegner EA, Oxenham V, Close J, Caplan GA. Regional cerebral hypometabolism on 18F-FDG PET/CT scan in delirium is independent of acute illness and dementia. Alzheimers Dement. 2023;19:97–106.

Article  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–82.

Article  PubMed  Google Scholar 

Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol. 2019;37:1020–120.

Article  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019;382:610–21.

Article  PubMed  PubMed Central  Google Scholar 

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA Trial. J Clin Oncol. 2020;38:3138–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Linzer RW, Guida DL, Aminov J, Snider JM, Khalife G, Buyukbayraktar AB, et al. Dihydroceramide desaturase 1 (DES1) promotes anchorage-independent survival downstream of HER2-driven glucose uptake and metabolism. FASEB J. 2022;36: e22558.

Article  CAS  PubMed  Google Scholar 

Kyeong S, Cha YJ, Ahn SG, Suh SH, Son EJ, Ahn SJ. Subtypes of breast cancer show different spatial distributions of brain metastases. PLoS ONE. 2017;12: e0188542.

Article  PubMed  PubMed Central  Google Scholar 

Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, et al. Radiological patterns of brain metastases in breast cancer patients: a subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. Int J Mol Sci. 2016;17:1615.

Article  PubMed  PubMed Central  Google Scholar 

Ahn SJ, Park M, Bang S, Cho E, Ahn SG, Suh SH, et al. Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression. Sci Rep. 2018;8:9947.

Article  PubMed  PubMed Central  Google Scholar 

Ulu E, Ozturk B, Atalay K, Okumus IB, Erdem D, Gul MK, et al. Diffusion-weighted imaging of brain metastasis: correlation of MRI parameters with histologic type. Turk Neurosurg. 2022;32:58–68.

PubMed  Google Scholar 

Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. Eur J Radiol. 2021;144: 109948.

Article  PubMed  Google Scholar 

Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases. Magn Reson Imaging. 2023;96:60–6.

Article  CAS  PubMed  Google Scholar 

Young JR, Ressler JA, Shiroishi MS, Mortimer JE, Schmolze D, Fitzgibbons M, et al. Association of relative cerebral blood volume from dynamic susceptibility contrast-enhanced perfusion MR with HER2 status in breast cancer brain metastases. Acad Radiol. 2023;30:1816–22.

Article  PubMed  Google Scholar 

Comments (0)

No login
gif